Jennison Associates
GPCR icon

Jennison Associates’s Structure Therapeutics GPCR Stock Holding History

Jennison Associates’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-314,503
Closed -$12.4M – 583
2024
Q2 		$12.4M Buy
+314,503
New +$12.9M 0.01% 365
2023
Q4 		– Sell
-420,479
Closed -$21.2M – 601
2023
Q3 		$21.2M Buy
420,479
+20,699
+5% +$667K 0.02% 309
2023
Q2 		$16.6M Hold
399,780
– – 0.01% 337
2023
Q1 		$9.51M Buy
+399,780
New +$9.39M 0.01% 395

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates's GPCR Position: Q3 2024 in Review

Jennison Associates sold out of Structure Therapeutics (GPCR) in Q3 2024, closing a stake of 314,503 shares — an estimated $12.4M sold.

Jennison Associates first reported a position in GPCR in Q1 2023 and held it in 4 quarters. The position peaked at $21.2M in Q3 2023. 160 funds tracked by Wall St. Rank hold GPCR as of Q3 2024.

  • Jennison Associates reported no remaining Structure Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jennison Associates sold 314,503 Structure Therapeutics shares in Q3 2024, an estimated $12.4M.
  • Jennison Associates first reported a position in Structure Therapeutics in Q1 2023 and held it in 4 quarters.
  • Jennison Associates's Structure Therapeutics position peaked at $21.2M in Q3 2023.
  • 160 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2024.

Based on Jennison Associates's 13F filing for Q3 2024, filed 8 Nov 2024.